s researchers rummage through a pantry of potential next-generation immunotherapies, they have developed a handful of new technologies they hope can be deployed against cancer: Natural killer cells. Neoantigen vaccines. Tumor-infiltrating lymphocytes.
Then there are T cell receptor, or TCR, therapies. In some ways, they’re similar to the CAR-T therapies that are already being used to treat some patients. But their potential to swarm and invade difficult-to-treat cancers, including solid tumors, has spurred hopes that they can significantly expand the population of patients who respond to immunotherapies.